POPIMAGE: Peri-operative Inflammaging in the Elderly After Surgery

Sponsor
University of Bonn (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05368896
Collaborator
(none)
150
21

Study Details

Study Description

Brief Summary

The population older than 80 years will significantly increase in the near future. Older patients' cognitive and physical status is known to deteriorate after surgery, leading to a high 30-day mortality due to post-operative comorbidities. Aging and related diseases share immune-related pathomechanisms. During aging, a chronic, low-grade sterile inflammation, called inflamaging, gradually develops. This likely results from low-grade innate immune activation and a functional, epigenomic and transcriptomic reprogramming of immune cells. Based on the hypothesis that surgical trauma leads to misplaced or altered self-molecules, which exacerbate inflammation and the postoperative risk for morbidity and mortality in elderly patients. There is increasing evidence that the individual's pre-operative immunobiography determines the susceptibility to peri-operative inflammation and post-operative outcome. Current exploratory pilot study will thus perform phenotyping of patients above 80 years undergoing major surgery. Participants will be evaluated for acute and long-term outcomes, including all-cause mortality, physical and cognitive function. To assess the individual's immunobiography, participants will be characterised by inflammation biomarkers combined with immunophenotyping, functional assays, and (epi-) genomic analyses before and after surgery. The cognitive impairment will be evaluated by measuring markers of neurodegeneration and neuropsychiatric testing and relate findings to volumetric imaging using high-resolution MRI to identify brain changes associated with cognitive decline.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    150 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Peri-OPerative InflamMAGing in Elderly Patients Undergoing Major Surgery: Prediction and Pathomechanisms of Post-operative Morbidities
    Anticipated Study Start Date :
    Jul 1, 2022
    Anticipated Primary Completion Date :
    Oct 30, 2023
    Anticipated Study Completion Date :
    Mar 30, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Elderly patients with postoperative complications after major surger

    Patients >80 years that will undergo major visceral or orthopedic surgery

    Outcome Measures

    Primary Outcome Measures

    1. Peri-interventional (surgical and non-surgical interventional) all-cause mortality rate on day 30 [30 days]

      Number of patients with death from any cause

    2. In-hospital outcome according to the ACS National Surgical Quality Improvement Program® (ACS NSQIP®) [30 days]

      Number of patients with e.g. pneumonia, cardiovascular complication, surgical site infection, urinary tract infection, venous thromboembolism, acute or progressive renal failure and re-surgery

    Secondary Outcome Measures

    1. Analysis of the new-onset of serious cardiac complications [30 days]

      Number of patients with serious cardiac complication Cardiac complication is defined according to the American Heart Association

    2. Analysis of the new-onset of serious pulmonary complications [30 days]

      Number of patients with Pneumonia: Clinical or radiological diagnosis. or Pulmonary embolism: Radiological diagnosis. Signs of pneumonia or pulmonary embolism in the autopsy

    3. Analysis of the new-onset of acute stroke [30 days]

      Number of patients with new-onset of acute stroke, defined as a new focal or generalised neurological deficit of >24h duration in motor, sensory, or coordination functions with compatible brain imaging and confirmed by a neurologist. Transient ischemic attack is not considered as acute stroke. Signs of stroke in the autopsy.

    4. Analysis of the new-onset of acute kidney injury [30 days]

      Number of patients with new-onset of acute kidney injury, defined according to the AKIN classification as AKI stage ≥2. This means increase of creatinine >2-3x from baseline within the hospital stay. Or urine output less than 0.5 ml kg-1 per hour for more than 12 hours. Or signs of acute kidney injury in the autopsy.

    5. Unplanned intensive care unit admission [30 days]

      Number of patients

    6. Unplanned intubation after intervention [30 days]

      Number of patients

    7. Analysis of the new-onset of sepsis [30 days]

      Number of patients diagnoses by SEPSIS-3 definition

    8. Analysis of the new-onset surgical side infection [30 days]

      Number of patients

    9. Ventilator dependency >48 h [48 hours]

      duration of mechanical ventilation

    10. Analysis of the new-onset thrombosis [30 days]

      number of patients with (deep) vein thrombosis

    11. all cause mortality [12 month]

      Number of patients with death from any cause

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    80 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age ≥ 80 years

    • elective major surgery defined as knee / hip replacement, spondylodesis (> 2 levels), gastrectomy, resection of esophagus, liver, pancreas, colon, rectum or lung

    Exclusion Criteria:
    • no informed consent

    • not able to perform neurocognitive testing

    • preexisting infection systemic: CRP>100 mg/l, Leukos >12.0 G/l or clinical signs

    Prosthetic joint infection (MSIS 2011 criteria):

    PJI is present when 1 major criteria exist or 4 out of 6 minor criteria exist

    Major criteria:
    • 2 positive periprosthetic cultures with phenotypically identical organisms

    • A sinus tract communicating with the joint

    Minor criteria:
    • Elevated CRP and ESR

    • Elevated synovial fluid WBC count or ++ change on leukocyte esterase test strip

    • Elevated synovial fluid PMN%

    • Presence of purulence in the affected joint

    • Positive histologic analysis of periprosthetic tissue

    • A single positive culture

    • Immunosuppression (HIV, glucocorticoids, immunosupressants)

    • Autoimmune diseases

    • ongoing or recent (<3 months) chemo/radiotherapy

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Bonn

    Investigators

    • Study Chair: Mark Coburn, Prof, mark.coburn@ukbonn.de

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Christian Bode, Principal Investigator, University of Bonn
    ClinicalTrials.gov Identifier:
    NCT05368896
    Other Study ID Numbers:
    • KAI-1
    First Posted:
    May 10, 2022
    Last Update Posted:
    May 24, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr. Christian Bode, Principal Investigator, University of Bonn
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 24, 2022